Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Kraig Biocraft Laboratories, Inc. (KBLB) has successfully completed the rearing of the first generation of its new BAM-1 parental strains during its spring production trial. The Company exceeded all expectations and control parameters for cocoon production, with the guidance of a top sericulture expert. The BAM-1 parental lines demonstrated excellent growth rates and robustness, paving the way for large-scale production. The Company is now focused on breeding the next generation of production hybrid silkworms to further scale up production.

Positive

• Kraig Biocraft Laboratories has successfully completed the rearing of the first generation of its BAM-1 parental strains in the spring production trial.
• The Company exceeded all expectations and control parameters for cocoon production in the trials.
• Dr. Nirmal Kumar, a top sericulture expert, oversaw the trials and praised the robustness of the BAM-1 parental lines.
• The Company is now ready to scale up production after confirming the readiness of the BAM-1 line.
• The BAM-1 hybrids showed faster growth rates, nearly perfect cocooning rates, and larger cocoon size compared to previous strains.
• The Company is on track to reach metric-ton-level production with the success of the trials.

Negative

• None.

ANN ARBOR, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial. Kraig Labs has successfully produced cocoon at rates that exceeded all expectations and control parameters for these trials.

Under the supervision and guidance of a top independent sericulture expert, Dr. Nirmal Kumar, whom the Company brought in to oversee these trials, Kraig Labs has now finished the critical rearing stage for both parental strains of the BAM-1 hybrid. Each parental strain was divided into two batches, creating a total of four separate production trial groups. The result was an absolute success, with all four production batches achieving excellent growth rates and nearly perfect cocooning.

Dr. Nirmal Kumar inspecting BAM-1 cocoons created by Kraig Labs

"I am very impressed with the robustness of the BAM-1 parental lines," said Dr. Nirmal Kumar. "The colony has exhibited perfect health and grown very quickly. The team's rearing skills are rapidly advancing, and they are ready to increase production. Based on what I have observed from rearing this first generation, I expect that the Company will have a very successful production scale-up."

The launch of these operations, after careful preparation and under the supervision of a renowned sericultural expert, demonstrated that the BAM-1 parental lines meet the performance and robustness necessary for large-scale production. With the successful completion of cocooning, the Company can confirm that the BAM-1 line has proven it is ready for scale-up. Over the next two weeks the Company will collect the moths from these cocoons to breed the next generation of production hybrid silkworms and conclude the critical parental line trial.

Meticulous testing and screening of the silkworms throughout the entire rearing cycle proved that the BAM-1 lines are the strongest, most robust recombinant spider silk strains the Company has ever produced. With zero observation of disease within any of the four production batches, the Company and its consultants are now prepared to accelerate the drive to reach metric-ton-level production.

"The BAM-1 hybrids have exceeded our expectations thanks in part to our team, our outside consultants, and Dr. Nirmal Kumar's guidance," said Company founder and CEO, Kim Thompson. "Initial results have shown faster growth rates, nearly perfect cocooning rates, and larger cocoon size than we have seen even in our own R&D center. We are in an entirely new ball game now."

The current production trial will continue to run for two or three weeks. Additional data on each of the four production batches is being collected and processed. "We are 85% to 90% through the trial of the parental strains, and every single batch of our new strains sailed through what we expected to be the toughest challenges," continued Thompson. "Even in advance of the conclusion of the trials, I am happy to report that our two-year program of acclimation to the production environment appears to have been achieved."

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

Kraig Labs’ specialized recombinant spider silk silkworms spinning cocoons

Kraig Labs’ BAM-1 cocoons on mountage

BAM-1 spider silk cocoons under UV light

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/235faf6c-9e4a-4c2c-be14-0a04fd52fe43

https://www.globenewswire.com/NewsRoom/AttachmentNg/01bc0ef2-d774-4f4c-9ae3-7cbbb9036686

https://www.globenewswire.com/NewsRoom/AttachmentNg/a2a2ca16-54e0-4ff0-b9c5-96f95c7b5fac

https://www.globenewswire.com/NewsRoom/AttachmentNg/25a30c2c-2bc5-4309-8fbc-f73a7142a4de

FAQ

What milestone did Kraig Biocraft Laboratories (KBLB) announce in the press release?

Kraig Biocraft Laboratories announced the successful completion of the rearing of the first generation of its new BAM-1 parental strains in the spring production trial.

Who oversaw the spring production trial of Kraig Biocraft Laboratories (KBLB)?

Dr. Nirmal Kumar, a top independent sericulture expert, oversaw the spring production trial of Kraig Biocraft Laboratories.

What were the results of the cocoon production in the trials for Kraig Biocraft Laboratories (KBLB)?

The Company exceeded all expectations and control parameters for cocoon production in the trials.

What did Dr. Nirmal Kumar say about the BAM-1 parental lines in the press release?

Dr. Nirmal Kumar praised the robustness of the BAM-1 parental lines and expressed confidence in the Company's ability to scale up production.

What is the next focus for Kraig Biocraft Laboratories (KBLB) after completing cocoon production?

The Company is now focused on breeding the next generation of production hybrid silkworms to further scale up production.